Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 34, 2015, Pages E4726-E4734

  Zhang, Jian ^a   Lieu, Yen K ^a   Ali, Abdullah M ^a   Penson, Alex ^a   Reggio, Kathryn S ^a   Rabadan, Raul ^a   Raza, Azra ^a   Mukherjee, Siddhartha ^a   Manley, James L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Leukemia; Myelodysplastic syndromes; Pre mRNA splicing; Serine arginine rich proteins; Spliceosome

Indexed keywords

RNA BINDING PROTEIN; SERINE ARGININE RICH SPLICING FACTOR 2 PROTEIN; UNCLASSIFIED DRUG; CRISPR ASSOCIATED PROTEIN; NUCLEAR PROTEIN; RIBONUCLEOPROTEIN; RNA; SRSF2 PROTEIN, HUMAN;

ALLELE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARCINOGENESIS; CELL MUTANT; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DNA REPAIR; ESCHERICHIA COLI; EXON; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MITOCHONDRIAL DNA DEPLETION; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA BINDING; RNA SPLICING; SPLICEOSOME; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

BINDING SITES; CRISPR-ASSOCIATED PROTEINS; EXONS; HUMANS; MUTATION; NUCLEAR PROTEINS; RIBONUCLEOPROTEINS; RNA; RNA SPLICING;

EID: 84940511517     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1514105112     Document Type: Article

References (49)

1. Heaney ML, Golde DW (1999) Myelodysplasia. N Engl J Med 340(21):1649-1660.
2. Corey SJ, et al. (2007) Myelodysplastic syndromes: The complexity of stem-cell diseases. Nat Rev Cancer 7(2):118-129.
3. Yoshida K, et al. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478(7367):64-69.
4. Haferlach T, et al. (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28(2):241-247.
5. Thol F, et al. (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119(15):3578-3584.
6. Wu SJ, et al. (2012) The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 120(15):3106-3111.
7. Kim E, et al. (2015) SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27(5):617-630.
8. David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev 24(21):2343-2364.
9. Zhang J, Manley JL (2013) Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov 3(11):1228-1237.
10. Long JC, Caceres JF (2009) The SR protein family of splicing factors: Master regulators of gene expression. Biochem J 417(1):15-27.
11. Tacke R, Manley JL (1995) The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities. EMBO J 14(14):3540-3551.
12. Wu JY, Maniatis T (1993) Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell 75(6):1061-1070.
13. Kohtz JD, et al. (1994) Protein-protein interactions and 5?-splice-site recognition in mammalian mRNA precursors. Nature 368(6467):119-124.
14. Papaemmanuil E, et al.; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122(22):3616-3627, quiz 3699.
15. Daubner GM, Cléry A, Jayne S, Stevenin J, Allain FH (2012) A syn-anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well. EMBO J 31(1):162-174.
16. Shen S, et al. (2014) rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci USA 111(51):E5593-E5601.
17. Lopez-Bergami P, Lau E, Ronai Z (2010) Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer 10(1):65-76.
18. Mandel H, et al. (2001) The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 29(3):337-341.
19. Bieber LL (1988) Carnitine. Annu Rev Biochem 57:261-283.
20. Zhang X, et al. (2009) CDK5RAP2 is required for spindle checkpoint function. Cell Cycle 8(8):1206-1216.
21. Scita G, et al. (1999) EPS8 and E3B1 transduce signals from Ras to Rac. Nature 401(6750):290-293.
22. Hopwood B, Dalton S (1996) Cdc45p assembles into a complex with Cdc46p/Mcm5p, is required for minichromosome maintenance, and is essential for chromosomal DNA replication. Proc Natl Acad Sci USA 93(22):12309-12314.
23. Jiang P, Zhang D (2013) Maternal embryonic leucine zipper kinase (MELK): A novel regulator in cell cycle control, embryonic development, and cancer. Int J Mol Sci 14(11):21551-21560.
24. Haack TB, et al. (2012) Exome sequencing reveals De novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet 91(6): 1144-1149.
25. Ahsan H, et al.; Familial Breast Cancer Study (2014) A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. Cancer Epidemiol Biomarkers Prev 23(4):658-669.
26. Agrimi G, et al. (2004) Identification of the human mitochondrial S-adenosylmethionine transporter: Bacterial expression, reconstitution, functional characterization and tissue distribution. Biochem J 379(Pt 1):183-190.
27. Cavaloc Y, Bourgeois CF, Kister L, Stévenin J (1999) The splicing factors 9G8 and SRp20 transactivate splicing through different and specific enhancers. RNA 5(3):468-483.
28. Schaal TD, Maniatis T (1999) Selection and characterization of pre-mRNA splicing enhancers: Identification of novel SR protein-specific enhancer sequences. Mol Cell Biol 19(3):1705-1719.
29. Dreumont N, et al. (2010) Antagonistic factors control the unproductive splicing of SC35 terminal intron. Nucleic Acids Res 38(4):1353-1366.
30. Arrisi-Mercado P, Romano M, Muro AF, Baralle FE (2004) An exonic splicing enhancer offsets the atypical GU-rich 3? splice site of human apolipoprotein A-II exon 3. J Biol Chem 279(38):39331-39339.
31. Zahler AM, Damgaard CK, Kjems J, Caputi M (2004) SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing. J Biol Chem 279(11): 10077-10084.
32. Hallay H, et al. (2006) Biochemical and NMR study on the competition between proteins SC35, SRp40, and heterogeneous nuclear ribonucleoprotein A1 at the HIV-1 Tat exon 2 splicing site. J Biol Chem 281(48):37159-37174.
33. Caputi M, Zahler AM (2002) SR proteins and hnRNP H regulate the splicing of the HIV-1 tev-specific exon 6D. EMBO J 21(4):845-855.
34. Qian W, et al. (2011) Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic Acids Res 39(14):6161-6171.
35. Schaal TD, Maniatis T (1999) Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA. Mol Cell Biol 19(1):261-273.
36. Crovato TE, Egebjerg J (2005) ASF/SF2 and SC35 regulate the glutamate receptor subunit 2 alternative flip/flop splicing. FEBS Lett 579(19):4138-4144.
37. Bailey TL, et al. (2009) MEME SUITE: Tools for motif discovery and searching. Nucleic Acids Res 37(Web Server issue):W202-208.
38. Gozani O, Potashkin J, Reed R (1998) A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site. Mol Cell Biol 18(8):4752-4760.
39. Lander ES, et al.; International Human Genome Sequencing Consortium (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860-921, and corrections (2001) 411:720 and (2001) 412:565.
40. Shen S, et al. (2012) MATS: A Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data. Nucleic Acids Res 40(8):e61.
41. Brignatz C, et al. (2009) Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn. Mol Cell Biol 29(24):6438-6448.
42. Le Beau MM, et al. (1996) Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 88(6):1930-1935.
43. Fischer K, et al. (1997) Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood 89(6):2036-2041.
44. Huang R, et al. (2003) A specific splicing variant of SVH, a novel human armadillo repeat protein, is up-regulated in hepatocellular carcinomas. Cancer Res 63(13):3775-3782.
45. Zhou X, Yang G, Huang R, Chen X, Hu G (2007) SVH-B interacts directly with p53 and suppresses the transcriptional activity of p53. FEBS Lett 581(25):4943-4948.
46. Kim D, et al. (2013) TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14(4):R36.
47. Anders S, Pyl PT, Huber W (2015) HTSeq-a Python framework to work with highthroughput sequencing data. Bioinformatics 31(2):166-169.
48. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550.
49. Chen M, David CJ, Manley JL (2012) Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nat Struct Mol Biol 19(3): 346-354.